Aspen Pharmacare Holdings Past Earnings Performance
Past criteria checks 1/6
Aspen Pharmacare Holdings has been growing earnings at an average annual rate of 16.8%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 4.6% per year. Aspen Pharmacare Holdings's return on equity is 5.2%, and it has net margins of 9.9%.
Key information
16.8%
Earnings growth rate
17.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 4.6% |
| Return on equity | 5.2% |
| Net Margin | 9.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think Shareholders May Want To Consider A Review Of Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Package
Nov 29
Aspen Pharmacare Holdings Limited (JSE:APN) Not Lagging Market On Growth Or Pricing
Nov 09Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings
Oct 10Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden
Oct 01Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59
Sep 10We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt
May 08Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable
Mar 05Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Dec 22Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30Revenue & Expenses Breakdown
How Aspen Pharmacare Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 44,706 | 4,404 | 10,100 | 0 |
| 31 Mar 24 | 43,703 | 4,636 | 9,936 | 0 |
| 31 Dec 23 | 42,700 | 4,868 | 9,771 | 0 |
| 30 Sep 23 | 41,705 | 5,048 | 9,583 | 0 |
| 30 Jun 23 | 40,709 | 5,228 | 9,394 | 0 |
| 31 Mar 23 | 39,542 | 5,515 | 9,127 | 0 |
| 31 Dec 22 | 38,375 | 5,802 | 8,859 | 0 |
| 30 Sep 22 | 38,491 | 6,145 | 8,692 | 0 |
| 30 Jun 22 | 38,606 | 6,488 | 8,525 | 0 |
| 31 Mar 22 | 38,560 | 6,185 | 8,656 | 0 |
| 31 Dec 21 | 38,514 | 5,881 | 8,796 | 0 |
| 30 Sep 21 | 38,140 | 5,340 | 8,955 | 0 |
| 30 Jun 21 | 37,766 | 4,798 | 9,114 | 0 |
| 31 Mar 21 | 35,760 | 3,954 | 8,866 | 0 |
| 31 Dec 20 | 36,308 | 3,782 | 9,075 | 0 |
| 30 Sep 20 | 34,984 | 3,581 | 8,976 | 0 |
| 30 Jun 20 | 33,659 | 3,380 | 8,876 | 0 |
| 31 Mar 20 | 39,927 | 3,272 | 9,988 | 0 |
| 31 Dec 19 | 33,620 | 870 | 8,954 | 0 |
| 30 Sep 19 | 34,567 | 1,275 | 9,154 | 0 |
| 30 Jun 19 | 35,514 | 1,679 | 9,354 | 0 |
| 31 Mar 19 | 36,880 | 3,350 | 9,612 | 0 |
| 31 Dec 18 | 36,683 | 4,890 | 9,575 | 0 |
| 30 Sep 18 | 37,499 | 5,256 | 9,573 | 0 |
| 30 Jun 18 | 38,314 | 5,621 | 9,570 | 0 |
| 31 Mar 18 | 39,618 | 5,682 | 9,678 | 0 |
| 31 Dec 17 | 40,922 | 5,743 | 9,786 | 0 |
| 30 Sep 17 | 41,068 | 5,436 | 9,636 | 0 |
| 30 Jun 17 | 41,213 | 5,128 | 9,485 | 0 |
| 31 Mar 17 | 39,557 | 4,414 | 9,293 | 0 |
| 31 Dec 16 | 37,900 | 3,700 | 9,100 | 0 |
| 30 Sep 16 | 36,750 | 4,000 | 8,850 | 0 |
| 30 Jun 16 | 35,600 | 4,300 | 8,600 | 0 |
| 31 Mar 16 | 35,583 | 5,220 | 8,553 | 0 |
| 31 Dec 15 | 35,567 | 6,140 | 8,506 | 0 |
| 30 Sep 15 | 35,833 | 5,670 | 8,503 | 0 |
| 30 Jun 15 | 36,100 | 5,200 | 8,500 | 0 |
| 31 Mar 15 | 35,836 | 5,369 | 8,071 | 0 |
| 31 Dec 14 | 35,572 | 5,537 | 7,641 | 0 |
| 30 Sep 14 | 32,544 | 5,272 | 6,847 | 0 |
| 30 Jun 14 | 29,515 | 5,008 | 6,054 | 0 |
| 31 Mar 14 | 25,901 | 4,388 | 5,200 | 0 |
| 31 Dec 13 | 22,287 | 3,768 | 4,346 | 0 |
Quality Earnings: APN has a large one-off loss of ZAR1.9B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: APN's current net profit margins (9.9%) are lower than last year (12.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APN's earnings have grown by 16.8% per year over the past 5 years.
Accelerating Growth: APN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: APN had negative earnings growth (-15.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.7%).
Return on Equity
High ROE: APN's Return on Equity (5.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 00:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aspen Pharmacare Holdings Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andre Bekker | Arqaam Capital Research Offshore S.A.L. |
| Boitshepo Seruwe | Avior Capital Markets |
| Simon Mather | Barclays |